Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 20, 2025 15:19 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market
June 17, 2025 08:30 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology
June 04, 2025 08:30 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
May 15, 2025 09:00 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

Lipella Pharmaceuticals to Present Phase 2a Data for LP-10 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting
April 23, 2025 08:30 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine”

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference
April 22, 2025 05:30 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025
April 08, 2025 05:00 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus
March 31, 2025 11:00 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast
February 11, 2025 05:46 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
February 06, 2025 06:00 ET | Source: Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

Next Page keyboard_arrow_right